

Lassa Hemorrhagic Fever Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Lassa Hemorrhagic Fever

<https://marketpublishers.com/r/L570E2F5D5EEN.html>

Date: September 2018

Pages: 65

Price: US\$ 1,200.00 (Single User License)

ID: L570E2F5D5EEN

Abstracts

Lassa Hemorrhagic Fever Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Lassa Hemorrhagic Fever Infection pipeline products.

DISEASE OVERVIEW

Lassa Hemorrhagic Fever infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as 'lockjaw' as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

REPORT DESCRIPTION

The Lassa Hemorrhagic Fever Infection pipeline guide presents complete overview of drugs currently being developed for Lassa Hemorrhagic Fever Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Lassa Hemorrhagic Fever Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Lassa Hemorrhagic Fever Infection pipeline candidates is included.

Major companies participating in therapeutic development of Lassa Hemorrhagic Fever Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Lassa Hemorrhagic Fever Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Lassa Hemorrhagic Fever Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Lassa Hemorrhagic Fever Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF LASSA HEMORRHAGIC FEVER INFECTION PIPELINE REPORT INCLUDES

Panorama of Lassa Hemorrhagic Fever Infection pipeline markets including statistics on therapeutic drugs and companies involved

Lassa Hemorrhagic Fever Infection Pipeline candidates across various

development phases including both pre-clinical, discovery and clinical stages are covered

Lassa Hemorrhagic Fever Infection pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Lassa Hemorrhagic Fever Infection pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Lassa Hemorrhagic Fever Infection pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Lassa Hemorrhagic Fever Infection pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Lassa Hemorrhagic Fever Infection pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Lassa Hemorrhagic Fever Infection Pipeline include

Number of Companies with Lassa Hemorrhagic Fever Infection projects in pre-clinical Development

Number of Companies with Lassa Hemorrhagic Fever Infection projects in Clinical Development

Lassa Hemorrhagic Fever Infection Pipeline Companies based in Americas

Lassa Hemorrhagic Fever Infection Pipeline Companies based in Europe

Lassa Hemorrhagic Fever Infection Pipeline Companies based in Asia Pacific

Lassa Hemorrhagic Fever Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include

Lassa Hemorrhagic Fever Infection Pipeline Agents in Pre- clinical/Discovery stage of Development

Lassa Hemorrhagic Fever Infection Pipeline Agents in Clinical Development stage

Lassa Hemorrhagic Fever Infection Pipeline Therapeutic Compounds received special status

Mechanism of Action of most pipeline Drugs

Small molecules among the Lassa Hemorrhagic Fever Infection Pipeline agents

II. INSIGHTS INTO LASSA HEMORRHAGIC FEVER INFECTION PIPELINE

1. Disease Overview

Introduction to Lassa Hemorrhagic Fever Infection

Symptoms and Causes of Lassa Hemorrhagic Fever Infection

Treatment or Prevention Options for Lassa Hemorrhagic Fever Infection

Other Details

2. Phase wise Pipeline Compounds

Lassa Hemorrhagic Fever Infection Pipeline Pre- Clinical/Discovery stage Drugs

Lassa Hemorrhagic Fever Infection Pipeline Phase 1 stage Drugs

Lassa Hemorrhagic Fever Infection Pipeline Phase 2 stage Drugs

Lassa Hemorrhagic Fever Infection Pipeline Phase 3 stage Drugs

Lassa Hemorrhagic Fever Infection Pipeline Pre-Registration stage Drugs

3. Company wise Lassa Hemorrhagic Fever Infection Pipeline Compounds

4. Lassa Hemorrhagic Fever Infection Pipeline by Mechanism of Action

III. LASSA HEMORRHAGIC FEVER INFECTION PIPELINE COMPOUND DETAILS

CC-11050

GEO-LM01

lassa fever vaccine

LHF-535

ML29

Arevirumab

Antivirals for Lassa Fever

NPC1 inhibitor for lassa fever

INO-4500

VesiculoVax

lassa fever vaccine

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. LASSA HEMORRHAGIC FEVER INFECTION PIPELINE COMPANY BRIEFS

Celgene Corp

GeoVax Labs Inc

Medigen Inc

Kineta Inc

Medigen Inc

Zalgen Labs LLC

RetroVirox Inc

H&P Labs Inc

Inovio Pharmaceuticals

Profectus Biosciences

Themis Bioscience

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL LASSA HEMORRHAGIC FEVER INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Lassa Hemorrhagic Fever Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Lassa Hemorrhagic Fever

Product link: <https://marketpublishers.com/r/L570E2F5D5EEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L570E2F5D5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970